POELLATH advises STADA management on investment by CapVest

London-based private equity firm CapVest Partners LLP (“CapVest”) has acquired a majority stake in STADA Arzneimittel AG (“STADA”), a leading manufacturer of high-quality pharmaceuticals. The sellers are Bain Capital and Cinven, which will each retain a minority stake in STADA. The parties have agreed not to disclose the financial details of the transaction. The transaction is still subject to the standard regulatory approvals and is expected to be completed in the first half of 2026.

STADA Arzneimittel AG, based in Bad Vilbel (near Frankfurt am Main), was acquired by Bain Capital and Cinven in 2017 and subsequently delisted from the stock exchange. Since then, the two investors have supported the company’s transformation from a German generic drug manufacturer to a leading global healthcare and pharmaceutical platform. With more than 25 targeted acquisitions – including Johnson & Johnson’s Nizoral brand, Walmark and portfolios of various consumer healthcare brands from GlaxoSmithKline and Sanofi – the company has significantly expanded its market presence. Today, STADA is one of Europe’s leading healthcare and pharmaceutical companies, focusing on consumer healthcare, generics, and specialty pharmaceuticals. The company distributes its products in more than 120 countries and employs around 11,600 people worldwide.

POELLATH advised the management of STADA on the management participation in relation to the investment by CapVest with the following Munich team:

• Dr. Benedikt Hohaus (partner, management participation, M&A/PE)
• Silke Simmer (counsel, management participation, M&A/PE)
• Ida Süss (senior associate, management participation, M&A/PE)